The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses
| Autor: | Peter Carmeliet, Anna Rita Cantelmo, Peter C. Stapor, Jermaine Goveia, Stijn Moens |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Vascular Endothelial Growth Factor A
Stromal cell Angiogenesis Endocrinology Diabetes and Metabolism medicine.medical_treatment Immunology Myocytes Smooth Muscle Angiogenesis Inhibitors Bone Marrow Cells Disease General Biochemistry Genetics and Molecular Biology chemistry.chemical_compound Neoplasms medicine Tumor Microenvironment Immunology and Allergy Humans Myeloid Cells Tumor microenvironment Neovascularization Pathologic business.industry Growth factor Cancer Endothelial Cells Fibroblasts medicine.disease Blockade Vascular endothelial growth factor chemistry Cancer research business Signal Transduction |
| Zdroj: | Cytokinegrowth factor reviews. 25(4) |
| ISSN: | 1879-0305 |
| Popis: | Vascular endothelial growth factor (VEGF) is a key growth factor driving angiogenesis (i.e. the formation of new blood vessels) in health and disease. Pharmacological blockade of VEGF signaling to inhibit tumor angiogenesis is clinically approved but the survival benefit is limited as patients invariably acquire resistance. This is partially mediated by the intrinsic flexibility of tumor cells to adapt to VEGF-blockade. However, it has become clear that tumor stromal cells also contribute to the resistance. Originally, VEGF was thought to specifically target endothelial cells (ECs) but it is now clear that many stromal cells also respond to VEGF signaling, making anti-VEGF therapy more complex than initially anticipated. A more comprehensive understanding of the complex responses of stromal cells to VEGF-blockade might inform the design of improved anti-angiogenic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect